Intelligence Feed event · Policy · 2026-09-26

    C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data

    Question

    C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data

    Direct answer

    At the 23rd International Myeloma Society Annual Meeting, C4 Therapeutics presented biomarker results from clinical trials evaluating its molecular glue degrader, cemsidomide. The Phase 1 data evaluating cemsidomide combined with dexamethasone highlighted measurable T-cell activation in relapsed or refractory multiple myeloma cohorts, while preliminary combination data with BCMA bispecific antibody elranatamab indicated complementary immune engagement.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-26
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data”, revision 1, evidence through 2026-09-26. https://marketontology.com/market-events/2026-09-26/c4-therapeutics-presents-cemsidomide-multiple-myeloma-phase-1-biomarker-data-7545ee

    POLICY
    C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data
    At the 23rd International Myeloma Society Annual Meeting, C4 Therapeutics presented biomarker results from clinical trials evaluating its molecular glue degrader, cemsidomide. The Phase 1 data evaluating cemsidomide combined with dexamethasone highlighted measurable T-cell activation in relapsed or refractory multiple myeloma cohorts, while preliminary combination data with BCMA bispecific antibody elranatamab indicated complementary immune engagement.
    CCCC
    Impact
    60
    SEP 26
    SIG
    90%
    CCCC
    C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data
    At the 23rd International Myeloma Society Annual Meeting, C4 Therapeutics presented biomarker results from clinical trials evaluating its molecular glue degrader, cemsidomide. The Phase 1 data evaluating cemsidomide combined with dexamethasone highlighted measurable T-cell activation in relapsed or refractory multiple myeloma cohorts, while preliminary combination data with BCMA bispecific antibody elranatamab indicated complementary immune engagement.
    → Positive biomarker activation readouts improve developmental probability-of-success metrics for CCCC's degrader pipeline, repricing early-stage clinical value.
    Impact
    At the 23rd International Myeloma Society Annual Meeting, C4 Therapeutics presented biomarker results from clinical trials evaluating its molecular glue degrader, cemsidomide. The Phase 1 data evaluating cemsidomide combined with dexamethasone highlighted measurable T-cell activation in relapsed or refractory multiple myeloma cohorts, while preliminary combination data with BCMA bispecific antibody elranatamab indicated complementary immune engagement.
    Affected
    CCCC
    Transmission
    Positive biomarker activation readouts improve developmental probability-of-success metrics for CCCC's degrader pipeline, repricing early-stage clinical value.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CCCCclinical pipeline de-risking via IMS biomarker validationUp1-5dSource details IMS Annual Meeting biomarker presentation showing T-cell activation in cemsidomide trials.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    CCCCUpdisagreed2.98 2026-09-25+4.53%-1.01%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month